Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lonza and Agennix have signed an agreement for the production of Agennix's talactoferrin, oral dendritic cell mediated immunotherapy (DCMI).
Subscribe to our email newsletter
As per the agreement, Lonza will produce commercial material at its microbial manufacturing facility in Kourim, Czech Republic.
With the agreement, Lonza will be able to seek approval as a second manufacturer of talactoferrin after the initial commercial launch.
Talactoferrin is currently in Phase III testing for the treatment of non-small cell lung cancer (NSCLC).
Lonza Custom Manufacturing COO Stephan Kutzer said: "Our partnership with Agennix is an example of this commitment and demonstrates Lonza’s ability to offer access to our development and manufacturing expertise at an early stage of production."
Agennix chief medical officer and management board member Rajesh Malik said: "In anticipation of positive Phase III data and a potential product approval, it is important that we have more than one manufacturer in place to ensure we can meet anticipated commercial demand and that we have security of supply."